Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04737486 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of AV-001 in Healthy Subjects
A Phase 1 study, sponsored by Vasomune Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04737486 is a Phase 1 study that has completed, run by Vasomune Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT04737486, a Phase 1 study, has completed, sponsored by Vasomune Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects. Safety and tolerability assessments will be conducted, and blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) and pharmacodynamics (PD) analysis.
Interventions
- OTHER Placebo
- DRUG AV-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-12-16 |
| Est. Completion | 2021-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04737486
The ClinicalTrials.gov registry entry for NCT04737486 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vasomune Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04737486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04737486 about?
NCT04737486 is a clinical study titled "A First-in-Human Study of AV-001 in Healthy Subjects". Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects. Safety and tolerability assessments will be conducted, and blood samples will be taken pre-dose and at several time points post-dose for pharma...
What is the current status of trial NCT04737486?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2020-12-16. Estimated completion is 2021-03-10.
What interventions are being tested in trial NCT04737486?
The interventions under investigation include: Placebo (OTHER), AV-001 (DRUG).
Who is sponsoring clinical trial NCT04737486?
This trial is sponsored by Vasomune Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.